AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35177415
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of tumor-infiltrating lymphocytes (TILs) after modified lymphodepleting regimen
Trial: 35177415
Drug: Modified lymphodepleting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified lymphodepleting regimen including intravenous cyclophosphamide (20 mg/kg for 3 days) and half dosage (100 mg) of PD1 antibody
Trial: 35177453
Drug: Initial non-operative
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial non-operative treatment (intravenous antibiotics with or without percutaneous drainage) for children with appendiceal mass and/or abscess
Trial: 35178092
Drug: Implant follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant follow-up for a mean duration of 7.22 years
Trial: 35178092
Drug: Implant characteristics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant characteristics including location, bone level, and number
Trial: 35178092
Drug: Clinical peri-implant
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical peri-implant and periodontal soft tissue statuses
Trial: 35178092
Drug: Peri-implant parameters
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-implant parameters
Trial: 35180010
Drug: Navitoclax (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax (50 mg once daily, escalating to a maximum of 300 mg once daily)
Trial: 35180010
Drug: Ruxolitinib (≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (≥ 10 mg twice daily)
Trial: 35180323
Drug: Decitabine and
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine and vorinostat with FLAG chemotherapy (fludarabine, cytarabine, and G-CSF)
Trial: 35180323
Drug: Decitabine and
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine and vorinostat with FLAG chemotherapy
Trial: 35180771
Drug: E7389-LF 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7389-LF 2.0 mg/m2 Q3W
Trial: 35180771
Drug: E7389-LF 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7389-LF 1.5 mg/m2 Q2W
Trial: 35180771
Drug: E7389-LF 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7389-LF 2.0 mg/m2 Q3W and 1.5 mg/m2 Q2W
Trial: 35181266
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SPPB and MoCA
Trial: 35181266
Drug: Nottingham Extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nottingham Extended Activities of Daily Living (IADL)
Trial: 35181498
Drug: Rezivertinib (BPI-7711)
RxNorm normalized name: Abivertinib
DrugBank: Abivertinib (DB15327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezivertinib (BPI-7711) at doses of 30 mg, 60 mg, 120 mg, 180 mg, 240 mg, 300 mg once daily until disease progression, unacceptable toxicity, or patient withdrawal
Trial: 35181499
Drug: Osimertinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib (80 mg once daily) plus durvalumab (3 or 10 mg/kg every 2 weeks) in part A
Trial: 35181499
Drug: Osimertinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib plus durvalumab (10 mg/kg every 2 weeks) in part B
Trial: 35181700
Drug: Optimal set
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal set of biomarkers selected by LASSO (NT-proBNP, ST2, vWF, FABP4, IGFBP-1, PAI-1, PON-3, transferrin receptor protein-1, chitotriosidase-1)
Trial: 35182224
Drug: G-atezo-pola (obinutuzumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-atezo-pola (obinutuzumab, atezolizumab, polatuzumab vedotin) at pola doses of 1.4 mg/kg
Trial: 35182224
Drug: G-atezo-pola (obinutuzumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-atezo-pola (obinutuzumab, atezolizumab, polatuzumab vedotin) at pola doses of 1.8 mg/kg
Trial: 35182224
Drug: G-atezo-pola
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-atezo-pola
Trial: 35182741
Drug: Direct-acting antivirals
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antivirals (DAAs) for hepatitis C
Trial: 35183167
Drug: Benralizumab therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab therapy
Trial: 35183221
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of concurrent chemotherapy (CC)
Trial: 35183221
Drug: Accumulated dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accumulated dose of cisplatin < 200 mg
Trial: 35185515
Drug: Home-based transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based transcranial direct current stimulation (tDCS) administered by study companions, 37 sessions over 12 weeks.
Trial: 35185515
Drug: Training program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training program for study companions to administer tDCS remotely.
Trial: 35185746
Drug: Digital Dance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital Dance for PD (10-h weekly sessions)
Trial: 35186675
Drug: Combined metabolic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined metabolic surgery (gastric bypass) plus medical therapy (CSM)
Trial: 35186675
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone (MTA)
Trial: 35187036
Drug: DGA-conforming diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DGA-conforming diet (DGAD) with 240 g/wk of salmon and albacore tuna
Trial: 35187383
Drug: intramuscular low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intramuscular low-dose testosterone
Trial: 35187951
Drug: Palbociclib, Letrozole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib, Letrozole, and Venetoclax combination therapy
Trial: 35187951
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy with a CDK4/6 inhibitor (gold standard treatment)
Trial: 35190519
Drug: Apatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib plus temozolomide (temozolomide 300 mg on days 1-5 and apatinib 500 mg daily every 28-day cycle)
Trial: 35190653
Drug: Radium-223 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radium-223 treatment
Trial: 35191018
Drug: Brodalumab 210
RxNorm normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab 210 mg /1·5 mL subcutaneously at weeks 0, 1, 2, 4 and every 2 weeks thereafter
Trial: 35191428
Drug: CYAD-101 (NKG2D-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYAD-101 (NKG2D-based CAR T-cell therapy)
Trial: 35192686
Drug: Inpatient chemotherapy
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient chemotherapy
Trial: 35192686
Drug: Antibiotic pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic pressure reduction
Trial: 35193825
Drug: Sibling cord
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibling cord blood cell infusion (12/12 HLA-matched)
Trial: 35193905
Drug: Psychiatric treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric treatment in the public health system of the Maule Region, Chile
Trial: 35193932
Drug: Toripalimab 1
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 1 or 3 mg/kg intravenously every 2 weeks combined with axitinib 5 mg orally two times per day
Trial: 35194187
Drug: Standard-of-care genotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care genotoxic radio-chemotherapy
Trial: 35195562
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) with full dose systemic chemotherapy; SBRT dosing: 60 Gy in 3 fractions for peripheral tumors, 50 Gy in 5 fractions for central tumors, 40-50 Gy in 5 fractions for hilar/mediastinal lymph nodes; Chemotherapy: 4 cycles of pemetrexed and cisplatin or carboplatin and paclitaxel for nonsquamous histology; cisplatin and docetaxel or cisplatin and paclitaxel for squamous histology; SBRT given between chemotherapy cycles with a 7-day break.
Trial: 35195837
Drug: Varlitinib combined
RxNorm normalized name: Varlitinib
DrugBank: Varlitinib (DB05944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varlitinib combined with paclitaxel (300 mg twice daily intermittently dosed)
Trial: 35196021
Drug: Cytokine-induced memory-like
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokine-induced memory-like (ML) NK cells stimulated with interleukin-12 (IL-12), IL-15, and IL-18.
Trial: 35196370
Drug: Ibrutinib plus
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib plus venetoclax (oral ibrutinib [420 mg/d]; oral venetoclax [5-week ramp-up to 400 mg/d])
Trial: 35196395
Drug: 15-min intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-min intravenous infusion of brivaracetam (up to 5 mg/kg/day, not exceeding 200 mg/day)
Trial: 35196395
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of brivaracetam (up to 5 mg/kg/day, not exceeding 200 mg/day)
Trial: 35196871
Drug: Flecainide acetate
RxNorm normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flecainide acetate inhalation solution (30 mg, 60 mg, 90 mg, 120 mg, and 120 mg with saccharin)
Trial: 35196871
Drug: Flecainide acetate
RxNorm normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flecainide acetate inhalation solution (120 mg with saccharin)
Trial: 35198648
Drug: Tocilizumab administration
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab administration
Trial: 35199231
Drug: High anti-HPV16
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High anti-HPV16 L1 antibody titers
Trial: 35199492
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (monotherapy)
Trial: 35199944
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for hypertension (having taken antihypertensives in the past 2 weeks)
Trial: 35199944
Drug: Control of
RxNorm normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control of hypertension (taking antihypertensives and having BP < 140/90 mmHg)
Trial: 35200588
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus an aromatase inhibitor
Trial: 35201621
Drug: Mifamurtide combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifamurtide combined with high-dose ifosfamide (HDIFO) for poor responders (PRs) after high-dose methotrexate, doxorubicin, and cisplatin (MAP) preoperatively.
Trial: 35201621
Drug: High-dose methotrexate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate, doxorubicin, and cisplatin (MAP) preoperatively.
Trial: 35203258
Drug: Innovative therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovative therapeutic schemes and drugs
Trial: 35205346
Drug: Copper tolerance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper tolerance treatment
Trial: 35210307
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for up to four doses, followed by nivolumab 480 mg every 4 weeks for ≤2 years)
Trial: 35210531
Drug: Intravenous 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.9 mg/kg alteplase within 4.5 h (ACS group)
Trial: 35210531
Drug: Intravenous 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.9 mg/kg alteplase within 4.5 h (PCS group)
Trial: 35210531
Drug: Intravenous 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.9 mg/kg alteplase within 4.5 h (ACS and PCS groups)
Trial: 35210606
Drug: mRNA-HB27-LNP; administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-HB27-LNP; administered intravenously; single prophylactic administration.
Trial: 35210606
Drug: mRNA-HB27-LNP; administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-HB27-LNP; administered prophylactically in a close contact transmission model.
Trial: 35211080
Drug: MyoPro™ orthosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MyoPro™ orthosis used in motor learning-based therapy
Trial: 35212017
Drug: Just-in-time adaptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Just-in-time adaptive interventions (JITAIs) during cognitive-behavioral therapy (CBT-E)
Trial: 35212017
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT-E) without JITAIs
Trial: 35212470
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug use and no experience of violence with ART
Trial: 35212470
Drug: Drug use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug use and experience of violence
Trial: 35212486
Drug: GLA gene
RxNorm normalized name: GLA
DrugBank: Gamolenic acid (DB13854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLA gene variant c.376A>G (p.Ser126Gly)
Trial: 35212640
Drug: Vaccine-promoting intervention
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-promoting intervention for vaccine hesitancy reduction
Trial: 35212779
Drug: Crenolanib (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenolanib (oral, once daily)
Trial: 35218024
Drug: Neural network
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neural network predicted rectal dose for patients with rectal spacer insertion
Trial: 35221224
Drug: Whole-body insulin
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body insulin clearance
Trial: 35221224
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity (M value)
Trial: 35221650
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pectoral type 1 (PECS I) and serratus plane block (SPB)
Trial: 35221928
Drug: Heterotopic Ossification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterotopic Ossification treatment, specific details not available
Trial: 35222036
Drug: SHR2285, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2285, a small-molecule Factor XIa inhibitor
Trial: 35222248
Drug: EVT after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVT after IV alteplase (combination-therapy group)
Trial: 35222719
Drug: Alprostadil treatment
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil treatment (Group A, n=52)
Trial: 35222719
Drug: Alprostadil plus
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil plus hyperbaric oxygen (HBO) treatment (Group B, n=52)
Trial: 35223458
Drug: Abemaciclib 200
RxNorm normalized name: abemaciclib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib 200 mg every 12 hours in combination with letrozole (Part A, n=20)
Trial: 35223458
Drug: Abemaciclib 200
RxNorm normalized name: abemaciclib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib 200 mg every 12 hours in combination with anastrozole (Part B, n=16)
Trial: 35223458
Drug: Abemaciclib 200
RxNorm normalized name: abemaciclib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib 200 mg every 12 hours in combination with tamoxifen (Part C, n=16)
Trial: 35223458
Drug: Abemaciclib 200
RxNorm normalized name: abemaciclib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib 200 mg every 12 hours in combination with exemestane (Part D, n=15)
Trial: 35223882
Drug: Initial photodynamic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial photodynamic therapy (PDT) with intravitreal injection of conbercept (IVC)
Trial: 35223882
Drug: Delayed photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed photodynamic therapy (PDT) with intravitreal injection of conbercept (IVC)
Trial: 35224534
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of linguistic and acoustic features in semi-structured conversations
Trial: 35226112
Drug: Sorafenib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib treatment for advanced HCC
Trial: 35227313
Drug: Telmisartan 40 mg/S-amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg/S-amlodipine 2.5 mg
Trial: 35227313
Drug: Telmisartan 80 mg
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg
Trial: 35229612
Drug: Direct Oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Oral Anticoagulant (DOAC) use in patients with MHCs
Trial: 35229827
Drug: Fractionated proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated proton radiation therapy (FPRT) to a total dose of 50.4 to 54 Gy RBE over 28 to 30 fractions
Trial: 35230138
Drug: Closed-Loop Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-Loop Insulin Delivery with a Pregnancy-Specific Zone Model Predictive Control Algorithm
Trial: 35230165
Drug: Prescription opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription opioid use in women living with HIV
Trial: 35230165
Drug: Prescription opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription opioid use in women without HIV
Trial: 35230254
Drug: Telemonitoring with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemonitoring with antihypertensive treatment titration
Trial: 35230974
Drug: Targeting collagens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeting collagens that signal through LAIR-1 in combination with blockade of TGF-β and PD-L1
Trial: 35232419
Drug: Interleukin-1 Receptor
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Interleukin-1 Receptor antagonist (IL-1Ra) measured in serum levels during 6 months follow-up.
Trial: 35234658
Drug: Self-monitoring intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-monitoring intervention using composite web-based multidimensional PA feedback with real-time daily feedback
Trial: 35234887
Drug: DPP Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPP Group Lifestyle Balance (GLB) program delivered via face-to-face groups or DVD with weekly telephonic coach contact
Trial: 35235414
Drug: Immune Checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune Checkpoint Inhibition as Single Therapy
Trial: 35235412
Drug: CDK 4/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK 4/6 inhibitors plus endocrine therapy
Trial: 35235572
Drug: Benzodiazepines <1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepines <1 mg/day
Trial: 35235572
Drug: Benzodiazepines >2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepines >2.5 mg/day
Trial: 35235572
Drug: Specific benzodiazepine
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific benzodiazepine agents
Trial: 35236302
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum carbonate (LC) for 8 weeks (1500-3000 mg total daily dose)
Trial: 35236302
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (CC) for 8 weeks (1500-6500 mg total daily dose) followed by LC for 8 weeks (1500-3000 mg total daily dose)
Trial: 35236302
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum carbonate (LC) for up to 6 months (1500-3000 mg total daily dose)
Trial: 35237053
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 600 mg every 12 h for 5-7 days